Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC
02/06/2026 13:06
BRIEF-Bristol-Myers Squibb Co - Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC June 2 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL-MYERS SQUIBB CO - IZALONTAMAB BRENGITECAN SHOWS SIGNIFICANT OS AND PFS IMPROVEMENTS IN TNBC AND ESCC
BRISTOL-MYERS SQUIBB CO - NDA FOR IZA-BREN IN ESCC ACCEPTED BY CHINA NMPA FOR PRIORITY REVIEW
BRISTOL-MYERS SQUIBB: IZA-BREN SHOWED MANAGEABLE SAFETY PROFILE IN THIS HEAVILY PRE-TREATED PATIENT POPULATION, WITH NO NEW SAFETY SIGNALS OBSERVED
Source text: ID:nBw7TYxLJa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC